Market Size of Global Mononucleosis Diagnostic Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
CAGR | 4.80 % |
Fastest Growing Market | Asia-Pacific |
Largest Market | North America |
Market Concentration | Low |
Major Players*Disclaimer: Major Players sorted in no particular order |
Mononucleosis Diagnostic Market Analysis
During the time frame of the forecast, the mononucleosis diagnostics market is expected to grow at a CAGR of nearly 4.8%.
The COVID-19 outbreak substantially impacted the mononucleosis diagnostics market as the pandemic increased the focus on the management of infectious diseases to limit their spread. This was attributed to the fact that COVID-19 was associated with Epstein-Barr virus (EBV) infections. For instance, as per an article published in September 2021 by BMC Infectious Diseases, out of the 128 patients with COVID-19, 13.3% were infected with Epstein-Barr virus reactivation. As per an update published in February 2022 by the University Health Network, long COVID-19 symptoms were also found in active EBV infections, and close to 70% of the COVID patients had reactivated EBV. It went on to say that EBV reactivation could be the cause of long COVID-19. Thus, such studies and updates indicate the demand for diagnosing EBV among the patient population increased during the pandemic. In addition, the market growth is stabilizing in the current scenario after COVID-19 as the worldwide restrictions have eased and the disease screening services have been resumed.
The major factors responsible for the growth of the global mononucleosis diagnostics market include rising health awareness and knowledge among patients, technological advancements leading to faster diagnosis, and the rise in the adolescent population. During the next few years, these factors are likely to continue to help the market grow.
Technological advancements leading to faster diagnosis are primarily driving the market's growth. For instance, in April 2021, Roche launched the Elecsys EBV panel, which consists of Elecsys EBV IgM, Elecsys EBV VCA IgG, and Elecsys EBV EBNA IgG immunoassays, in countries accepting the CE Mark. Additionally, in January 2022, Quanterix Corporation reported that its Simoa technology had been proven to be significant in identifying a high prevalence of EBV associated with multiple sclerosis (MS). Thus, growing technological advances in the mononucleosis diagnostics market are expected to increase demand over the forecast period.
Moreover, as per the study published in August 2022 by Frontiers in Immunology, within 10 years from the index date, the incidence of MS was 22.6 cases per 100,000 person-years among patients with infectious mononucleosis but only 11.9 cases per 100,000 person-years among individuals without infectious mononucleosis. So, the growing number of cases of mononucleosis is likely to help the study market grow over the next few years.
Still, the fact that there aren't many tests for diagnosing mononucleosis is a big reason why the market isn't growing faster.
Mononucleosis Diagnostic Industry Segmentation
As per the scope of the report, infectious mononucleosis, also called "mono," is a contagious disease. Epstein-Barr virus (EBV) is the most common cause of infectious mononucleosis, but other viruses can also cause this disease. It is common among teenagers and young adults, especially college students. Mononucleosis diagnostics refers to the detection of the Epstein-Barr virus (EBV). The market comprises various detection tests used for the diagnosis of mononucleosis. There are various tests available on the market, such as the monospot test, complete blood count test, and Epstein-Barr virus (EBV) antibody test. The mononucleosis diagnostics market is segmented by type of test (monospot test, complete blood count test, and Epstein-Barr virus (EBV) antibody test), end user (hospitals, laboratories, and other end users), and geography (North America, Europe, Asia-Pacific, the Middle East, Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report provides value in USD million for the aforementioned segments.
By Type of Test | |
Monospot Test | |
Complete Blood Count Test | |
Epstein Barr Virus (EBV) Antibody Test |
By End-User | |
Hospitals | |
Laboratories | |
Other End-Users |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Mononucleosis Diagnostic Market Size Summary
The mononucleosis diagnostics market is poised for steady growth, driven by increasing health awareness, technological advancements, and a rising adolescent population. The market experienced a significant impact due to the COVID-19 pandemic, which heightened the focus on infectious disease management, particularly related to Epstein-Barr virus (EBV) infections. This led to an increased demand for EBV diagnostics, as studies linked COVID-19 with EBV reactivation. As global restrictions eased, the market began stabilizing, with resumed disease screening services. Technological innovations, such as Roche's Elecsys EBV panel and Quanterix Corporation's Simoa technology, are expected to further propel market growth by enabling faster and more accurate diagnoses. Despite the limited number of diagnostic tests available, the monospot test is anticipated to dominate the market segment due to its high sensitivity and specificity, along with its cost-effectiveness and rapid antibody detection capabilities.
The Asia-Pacific region is projected to experience the highest growth rate in the mononucleosis diagnostics market, driven by a substantial adolescent population susceptible to EBV infections. The region's demographic trends, coupled with the presence of key industry players like Cardinal Health and Abbott, present significant market opportunities. The high prevalence of EBV and its association with mononucleosis, particularly among teenagers, underscores the demand for diagnostic tests. Major companies in the market are focusing on developing advanced products to enhance detection speed and accuracy. Recent innovations, such as Eurofins Viracor's T Cell test and Hologic's molecular assays, highlight the ongoing efforts to improve diagnostic capabilities, further supporting market expansion over the forecast period.
Global Mononucleosis Diagnostic Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rising Health Awareness and Knowledge among Patients
-
1.2.2 Rise in Prevalence of Mononucleosis
-
-
1.3 Market Restraints
-
1.3.1 Limitations of Available Tests for the Diagnosis of Mononucleosis
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD Million)
-
2.1 By Type of Test
-
2.1.1 Monospot Test
-
2.1.2 Complete Blood Count Test
-
2.1.3 Epstein Barr Virus (EBV) Antibody Test
-
-
2.2 By End-User
-
2.2.1 Hospitals
-
2.2.2 Laboratories
-
2.2.3 Other End-Users
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Global Mononucleosis Diagnostic Market Size FAQs
What is the current Global Mononucleosis Diagnostic Market size?
The Global Mononucleosis Diagnostic Market is projected to register a CAGR of 4.80% during the forecast period (2024-2029)
Who are the key players in Global Mononucleosis Diagnostic Market?
Abbott Laboratories, Thermo Fischer Scientific Inc., Danaher Corporation, Cardinal Health Inc. and Bio Rad Laboratories Inc. are the major companies operating in the Global Mononucleosis Diagnostic Market.